Genetic background influences therapeutic effectiveness of VEGF

被引:39
作者
Fukino, K
Sata, M [1 ]
Seko, Y
Hirata, Y
Nagai, R
机构
[1] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan
[2] JST, PRESTO, Saitama 3320012, Japan
关键词
angiogenesis; strain; VEGF; receptor; collateral; mouse;
D O I
10.1016/j.bbrc.2003.08.134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Therapeutic angiogenesis has emerged as a promising therapy, but some patients are refractory to exogenous growth factors. In order to identify the genetic determinants of post-natal angiogenesis and physiological vessel formation, we investigated the genetic factors that affected ischemia-induced development of collaterals in mice. An ischemic hindlimb model was generated in C57BL/6, C3H/He. and BALB/c mice. Angiogenesis was markedly different among the mice as determined by the restoration of blood perfusion and capillary density of the ischemic muscle. Impaired collateral vessel formation in BALB/c mice was associated with reduced expression of vascular endothelial cell growth factor (VEGF). Intramuscular gene transfer of VEGF promoted collateral formation in C57BL/6J mice, but not in BALB/c mice. Ineffectiveness of VEGF in BALB/c mice was associated with impaired expression of VEGF receptor. Our findings suggest that genetic background may influence spontaneous collateral formation and therapeutic effectiveness of exogenous VEGF. Alternative strategies other than administration of VEGF alone might be needed to attain optimal angiogenesis in some patients. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:143 / 147
页数:5
相关论文
共 24 条
  • [1] Gene transfer into muscle by electroporation in vivo
    Aihara, H
    Miyazaki, J
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (09) : 867 - 870
  • [2] Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
    Baumgartner, I
    Pieczek, A
    Manor, O
    Blair, R
    Kearney, M
    Walsh, K
    Isner, JM
    [J]. CIRCULATION, 1998, 97 (12) : 1114 - 1123
  • [3] VEGF gene therapy: stimulating angiogenesis or angioma-genesis?
    Carmeliet, P
    [J]. NATURE MEDICINE, 2000, 6 (10) : 1102 - 1103
  • [4] Couffinhal T, 1998, AM J PATHOL, V152, P1667
  • [5] Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice
    Couffinhal, T
    Silver, M
    Kearney, M
    Sullivan, A
    Witzenbichler, B
    Magner, M
    Annex, B
    Peters, K
    Isner, JM
    [J]. CIRCULATION, 1999, 99 (24) : 3188 - 3198
  • [6] Faraci FM, 1999, CIRC RES, V85, P1214
  • [7] Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis
    Folkman, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (26) : 1757 - 1763
  • [8] Therapeutic angiogenesis for ischemic cardiovascular disease
    Freedman, SB
    Isner, JM
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (03) : 379 - 393
  • [9] FREEMAN MR, 1995, CANCER RES, V55, P4140
  • [10] A physical map of the mouse genome
    Gregory, SG
    Sekhon, M
    Schein, J
    Zhao, SY
    Osoegawa, K
    Scott, CE
    Evans, RS
    Burridge, PW
    Cox, TV
    Fox, CA
    Hutton, RD
    Mullenger, IR
    Phillips, KJ
    Smith, J
    Stalker, J
    Threadgold, GJ
    Birney, E
    Wylie, K
    Chinwalla, A
    Wallis, J
    Hillier, L
    Carter, J
    Gaige, T
    Jaeger, S
    Kremitzki, C
    Layman, D
    Maas, J
    McGrane, R
    Mead, K
    Walker, R
    Jones, S
    Smith, M
    Asano, J
    Bosdet, I
    Chan, S
    Chittaranjan, S
    Chiu, R
    Fjell, C
    Fuhrmann, D
    Girn, N
    Gray, C
    Guin, R
    Hsiao, L
    Krzywinski, M
    Kutsche, R
    Lee, SS
    Mathewson, C
    McLeavy, C
    Messervier, S
    Ness, S
    [J]. NATURE, 2002, 418 (6899) : 743 - U3